We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bleb Vascularity Change After Subconjunctival Injection Bevacizumab

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2008 by Capital Medical University.
Recruitment status was:  Active, not recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00815594
First Posted: December 30, 2008
Last Update Posted: December 30, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Capital Medical University
  Purpose
The occurrence of conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery. Vascular endothelial growth factor is thought to be a key role in the formation of conjunctival scar, which play a pivotal role in the wound-healing process. So it seems that the recombinant human anti-VEGF antibody could inhibit angiogenesis, and reduce the conjunctival vascular formation in the wound-healing process after glaucoma filtering surgery.

Condition Intervention Phase
Bleb Vascularity Conjunctival Scarring Drug: bevacizumab Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Bleb Vascularity Change After Subconjunctival Injection of Bevacizumab

Resource links provided by NLM:


Further study details as provided by Capital Medical University:

Primary Outcome Measures:
  • bleb vascular change [ Time Frame: one day, one week, one month ]

Estimated Enrollment: 30
Study Start Date: December 2008
Estimated Study Completion Date: May 2009
Estimated Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: bevacizumab
    0.05ml, 1.25mg
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Glaucoma patients after trabeculectomy whose bleb is hyperaemia

Exclusion Criteria:

  • Affected eye has normal IOP
  • Not allergic with Avastin
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00815594


Locations
China, Beijing
Tongren hospital
Beijing, Beijing, China, 100730
Sponsors and Collaborators
Capital Medical University
Investigators
Principal Investigator: Liu Xuan, M.D. An ophthalmologist in Tongren hospital
  More Information

Responsible Party: Wang NingLi, Beiing Tongren hospital
ClinicalTrials.gov Identifier: NCT00815594     History of Changes
Other Study ID Numbers: 2008TR-LX-001
First Submitted: December 29, 2008
First Posted: December 30, 2008
Last Update Posted: December 30, 2008
Last Verified: December 2008

Keywords provided by Capital Medical University:
bleb
vascular change
bevacizumab
trabeculectomy
Bleb vascularity associated with increased scarring activity
Conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery
the recombinant human anti-VEGF antibody could inhibit angiogenesis of conjunctiva.

Additional relevant MeSH terms:
Cicatrix
Fibrosis
Pathologic Processes
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents